- Partners Group acquired Pharmathen in January 2022
- Pharmathen is a complex drug delivery and formulation developer
- Partners Group is a global private markets firm based in Baar-Zug, Switzerland
Pharmathen, backed by Partners Group, has acquired CBL Patras, a vertically integrated peptides manufacturer.
CBL provides peptide starting materials and intermediates as well as industrial and commercial-scale manufacturing of proprietary and generic GMP peptides. It is based in Patras, Greece.
The Barlos family, CBL’s founding family, will continue to work closely with Pharmathen and CBL’s management team to solidify and provide any required scale to support the growth of the integrated businesses globally, according to a release.
“This acquisition is expected to unlock substantial commercial and R&D pipeline synergies for both companies and expand the products and services that we offer to our customers,” said Dimitris Kadis, CEO of Pharmathen.
Partners Group completed the acquisition of Pharmathen from BC Partners in January 2022.
Partners Group is a global private markets firm with its regional headquarters in Baar-Zug, Switzerland.
Pharmathen is a complex drug delivery and formulation developer based in Athens, Greece.
Ropes & Gray served as advisor to Pharmathen.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
